Sustained treatment-free molecular remission after mini-hyper-CVD plus daratumumab in an elderly patient with CD38-high KMT2A::AFF1-positive B-cell acute lymphoblastic leukemia
Clinical Hematology International: Case Reports · 18.09.2026 · 1 (3)
DOI: 10.46989/001c.170434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Hematology International: Case Reports, online erschienen am 18.09.2026. Verfasst von Maxim Selivanov und 5 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
KMT2A-rearranged B-cell acute lymphoblastic leukemia (B-ALL) is associated with poor outcomes and a high risk of relapse, particularly in elderly patients. CD38 is frequently expressed on B-ALL blasts and represents a potential therapeutic target. We report a 72-year-old woman diagnosed with CD38-high (99%) KMT2A::AFF1-positive B-ALL presenting with hyperleukocytosis, generalized lymphadenopathy, and splenomegaly. Bone marrow flow cytometry demonstrated 84.4% blasts with an immunophenotype consistent with Pro-B acute lymphoblastic leukemia (B-I according to the EGIL classification). Cytogenetic and molecular studies confirmed t(4;11)(q21;q23) and KMT2A::AFF1 rearrangement. The patient received two cycles of mini-hyper-CVD combined with four weekly infusions of daratumumab (16 mg/kg). Morphologic remission was achieved after the first cycle. Following the second cycle, measurable residual disease (MRD) was negative by multiparameter flow cytometry (sensitivity, 10⁻⁴), and reverse-transcription polymerase chain reaction was negative for KMT2A::AFF1. Treatment was discontinued in December 2023 because of recurrent grade 3-4 cytopenias, febrile neutropenia, and severe infectious complications. Despite early cessation of therapy, serial bone marrow examinations demonstrated sustained remission. MRD remained negative, and repeated molecular monitoring consistently showed no detectable KMT2A::AFF1 transcripts. At the latest follow-up in April 2026, approximately 28 months after treatment discontinuation, the patient remained in treatment-free molecular remission. This observation suggests that daratumumab-containing regimens warrant further investigation in selected patients with CD38-high KMT2A-rearranged B-ALL.
Zitieren
APA
Selivanov, M., Klodzinsky, A., Zinchenko, A., Kakhanova, M., Baimurzina, A., & Lyssenko, A. (2026). Sustained treatment-free molecular remission after mini-hyper-CVD plus daratumumab in an elderly patient with CD38-high KMT2A::AFF1-positive B-cell acute lymphoblastic leukemia. Clinical Hematology International: Case Reports, 1(3). https://doi.org/10.46989/001c.170434
Vancouver
Selivanov M, Klodzinsky A, Zinchenko A, Kakhanova M, Baimurzina A, Lyssenko A. Sustained treatment-free molecular remission after mini-hyper-CVD plus daratumumab in an elderly patient with CD38-high KMT2A::AFF1-positive B-cell acute lymphoblastic leukemia. Clinical Hematology International: Case Reports. 2026;1(3). doi:10.46989/001c.170434
BibTeX
@article{Selivanov2026,
author = {Selivanov, Maxim and Klodzinsky, Anton and Zinchenko, Alyona and Kakhanova, Mariya and Baimurzina, Aliya and Lyssenko, Angelina},
title = {Sustained treatment-free molecular remission after mini-hyper-CVD plus daratumumab in an elderly patient with CD38-high KMT2A::AFF1-positive B-cell acute lymphoblastic leukemia},
journal = {Clinical Hematology International: Case Reports},
year = {2026},
volume = {1},
number = {3},
doi = {10.46989/001c.170434}
}
EUVIMED